Other research analysts also recently issued reports about the company. Shore Capital reiterated a buy rating on shares of Vectura Group in a research note on Thursday, January 4th. Panmure Gordon reiterated a buy rating and set a GBX 150 ($2.03) price objective on shares of Vectura Group in a research note on Thursday, November 9th. Numis Securities cut their price objective on Vectura Group from GBX 205 ($2.78) to GBX 170 ($2.31) and set a buy rating for the company in a research note on Thursday, November 9th. Peel Hunt reiterated a hold rating and set a GBX 160 ($2.17) price objective on shares of Vectura Group in a research note on Wednesday. Finally, Royal Bank of Canada upgraded Vectura Group to a sector performer rating and set a GBX 119 ($1.61) price objective for the company in a research note on Thursday, December 14th. Three research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company. The stock presently has an average rating of Buy and an average target price of GBX 174 ($2.36).
Vectura Group (VEC) opened at GBX 107.10 ($1.45) on Thursday. Vectura Group has a 52 week low of GBX 86.50 ($1.17) and a 52 week high of GBX 166.97 ($2.26).
TRADEMARK VIOLATION WARNING: “Vectura Group (VEC) Earns Overweight Rating from JPMorgan Chase & Co.” was reported by Sports Perspectives and is owned by of Sports Perspectives. If you are reading this article on another domain, it was stolen and reposted in violation of United States and international trademark & copyright laws. The correct version of this article can be read at https://sportsperspectives.com/2018/01/28/vectura-group-vec-earns-overweight-rating-from-jpmorgan-chase-co.html.
Vectura Group plc is engaged in research, development and commercialization of therapeutic products and drug delivery systems for human use. The Company’s products include Ultibro Breezhaler (European Union (EU) and Rest of World (RoW)) – LABA-LAMA; Seebri Breezhaler (EU and RoW) – LAMA; AirFluSal Forspiro (EU and RoW) – ICS-LABA; ADVATE (Global) – Antihaemophilic Factor (Recombinant); Adept (Global) – Icodextrin; Anoro Ellipta (Global) – LAMA-LABA; Relvar Ellipta/Breo Ellipta (Global) – ICS-LABA, and Incruse Ellipta (Global) – LAMA.
Receive News & Ratings for Vectura Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vectura Group and related companies with MarketBeat.com's FREE daily email newsletter.